Companies / enGene Therapeutics Inc. / Activity
Activity — enGene Therapeutics Inc.
6 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | Persistent Asset Partners Ltd 13F manager | New | Common Stock | $198.1K | +114K | 114,493 0.17% of shares | low |
| Q2 2026 as of | Privium Fund Management B.V. 13F manager | New | Common Stock | $294.1K | +170K | 170,000 0.25% of shares | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | New | Common Stock | $413.5K | +239K | 239,035 0.36% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | New | Common Stock | $2.34M | +344K | 343,928 0.51% of shares | low |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | Common stock | $7.82M | +1.1M | 1,148,997 1.72% of shares | medium |
| Q2 2026 as of | BML Capital Management, LLC 13F manager | New | Common Stock | $11.54M | +6.7M | 6,669,908 9.96% of shares | medium |